This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 5mg | $150 | 3-6 Days |
| 10mg | $250 | 3-6 Days |
| 25mg | $450 | 3-6 Days |
| 50mg | $750 | 3-6 Days |
| 100mg | $1250 | 3-6 Days |
| 250mg | $1950 | 3-6 Days |
: Cat #: V17221 CAS #: 38398-32-2 Purity ≥ 99%
Description: Ganaxolone (CCD-1042; C-1042; Ztalmy) is a novel, CNS-active and potent GABAA modulator. As of March 2022, the US FDA has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. This is the first treatment for seizures associated with CDD and the first treatment specifically for CDD. Ganaxolone acts on well-characterized targets in the brain known to have anxiolytic and anticonvulsant effects.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 332.528 |
|---|---|
| Molecular Formula | C22H36O2 |
| CAS No. | 38398-32-2 |
| SMILES Code | CC([C@H]1CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@](C)(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O |
| Synonyms | CCD-1042; CCD 1042; C1042; CCD-1042; Ztalmy |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 3.0073 mL | 15.0363 mL | 30.0727 mL | 60.1453 mL |
| 5mM | 0.6015 mL | 3.0073 mL | 6.0145 mL | 12.0291 mL |
| 10mM | 0.3007 mL | 1.5036 mL | 3.0073 mL | 6.0145 mL |
| 20mM | 0.1504 mL | 0.7518 mL | 1.5036 mL | 3.0073 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.